glycine has been researched along with POEMS Syndrome in 2 studies
POEMS Syndrome: A multisystemic disorder characterized by a sensorimotor polyneuropathy (POLYNEUROPATHIES), organomegaly, endocrinopathy, monoclonal gammopathy, and pigmentary skin changes. Other clinical features which may be present include EDEMA; CACHEXIA; microangiopathic glomerulopathy; pulmonary hypertension (HYPERTENSION, PULMONARY); cutaneous necrosis; THROMBOCYTOSIS; and POLYCYTHEMIA. This disorder is frequently associated with osteosclerotic myeloma. (From Adams et al., Principles of Neurology, 6th ed, p1335; Rev Med Interne 1997;18(7):553-62)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the safety and efficacy of a new proteasome inhibitor Ixazomib followed by autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of POEMS syndrome." | 8.12 | [Ixazomib-Based Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in the Treatment of POEMS Syndrome]. ( Cheng, H; Cheng, P; Guan, J; Wang, LL; Wang, QX; Zhou, Y; Zou, L, 2022) |
| "To investigate the safety and efficacy of a new proteasome inhibitor Ixazomib followed by autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of POEMS syndrome." | 4.12 | [Ixazomib-Based Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in the Treatment of POEMS Syndrome]. ( Cheng, H; Cheng, P; Guan, J; Wang, LL; Wang, QX; Zhou, Y; Zou, L, 2022) |
| " This study aimed to evaluate the efficacy and safety of the combination of ixazomib, lenalidomide, and dexamethasone (IRd) for POEMS syndrome." | 4.12 | Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( Aotsuka, Y; Kano, H; Kuwabara, S; Mimura, N; Misawa, S; Morooka, M; Nakamura, K; Ohwada, C; Otani, R; Sakaida, E; Sekiguchi, Y; Shibuya, K; Suichi, T; Takeda, Y; Tsukamoto, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, P | 1 |
| Wang, LL | 1 |
| Guan, J | 1 |
| Zhou, Y | 1 |
| Wang, QX | 1 |
| Cheng, H | 1 |
| Zou, L | 1 |
| Suichi, T | 1 |
| Misawa, S | 1 |
| Sekiguchi, Y | 1 |
| Shibuya, K | 1 |
| Nakamura, K | 1 |
| Kano, H | 1 |
| Aotsuka, Y | 1 |
| Otani, R | 1 |
| Morooka, M | 1 |
| Tsukamoto, S | 1 |
| Takeda, Y | 1 |
| Mimura, N | 1 |
| Ohwada, C | 1 |
| Sakaida, E | 1 |
| Kuwabara, S | 1 |
2 other studies available for glycine and POEMS Syndrome
| Article | Year |
|---|---|
[Ixazomib-Based Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in the Treatment of POEMS Syndrome].
Topics: Adult; Boron Compounds; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; | 2022 |
Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.
Topics: Boron Compounds; Dexamethasone; Endocrine System Diseases; Glycine; Humans; Lenalidomide; Monoclonal | 2022 |